Navigation Links
Nventa's CEO to present at two upcoming investor conferences
Date:10/2/2007

SAN DIEGO, CA, Oct. 2 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX:NVN) announced today that Gregory M. McKee, the Company's President and Chief Executive Officer, will present at two upcoming investor conferences:

BioContact Quebec 2007 (Quebec, Canada):

----------------------------------------

Mr. McKee is scheduled to present on Thursday, October 4th at

11:00 am (Eastern Time) in the Salle Laval Room at the Fairmont Le

Chateau Frontenac.

BIO Investor Forum (San Francisco, California):

-----------------------------------------------

Mr. McKee is scheduled to present on Wednesday, October 10th at

1:15 pm (Pacific Time) in the Twin Peaks South Room at the Palace

Hotel in San Francisco. A live webcast with supporting slides of this

presentation will be available via:

http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=NVN.TO&item_id=1660569

The replay of the webcast at BIO Investor Forum will be available

until January 10, 2008. (Due to its length, this URL may need to be

copied/pasted into your Internet browser's address field. Remove any

extra spaces if necessary.)

About Nventa Biopharmaceuticals Corporation:

--------------------------------------------

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol NVN.

For more information about Nventa Biopharmaceuticals Corporation and access to the BIO Investor Forum webcast, please visit the Company's website located at http://www.nventacorp.com.

CONTACT
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015  Renova™ Therapeutics, a biopharmaceutical company developing ... other chronic diseases, has engaged RAND Health Advisory ... reflect the healthcare patterns of multiple advanced heart ... used to characterize the impact the company,s lead ... groups of patients and the overall health care ...
(Date:5/5/2015)... DIEGO , May 5, 2015  A group ... formation of the Coma Research Institute, a non-profit organization ... patients and families suffering from disorders of consciousness.  ... - http://photos.prnewswire.com/prnh/20150504/213779LOGO   ... disorder of consciousness, in which no voluntary actions can ...
(Date:5/5/2015)... May 05, 2015 Research and Markets ... of the "Clinical Laboratory, Molecular Diagnostics and ... to 2019 - Global Version" report to ... in the area of molecular diagnostics and pharmacogenics ... evolving world market that is moving out of ...
(Date:5/5/2015)... , May 5, 2015  Orexigen Therapeutics, Inc. ... the first quarter 2015 on Friday, May 8 before ... a live webcast and conference call at 8:30 a.m. ... live call may be accessed by phone by calling ... 39586962. The webcast can be accessed live on the ...
Breaking Biology Technology:RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 5Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2
... 4 Researchers are taking a closer look at ... demonstrate that inhibiting this biological route suppresses tumor growth, ... The pathway is involved in angiogenesis, cell growth, differentiation, ... PI3/AKT/mTOR pathway, which plays a key role in cancer, ...
... Diagnostic,Systems, Inc., (OTC Bulletin Board: IMDS), a pioneer in ... evaluating the CTLM system as an,adjunct to mammography is ... (Logo: ... a radiologist at Charite Hospital in Berlin,Germany, authored "Near-infrared ...
... Hont, Chairman and Chief Executive Officer of Met-Pro Corporation (NYSE: ... their meeting on December 3, 2008, declared a quarterly dividend of ... record at the close of business on February 26, 2009. ... year. , , This is the ...
Cached Biology Technology:GEN Reports Growing Focus on PI3-Kinase Pathway in Cancer Research 2Imaging Diagnostic Systems CT Laser Mammography (CTLM) Technology Featured in Peer-Reviewed Journal 2Met-Pro Corporation Declares Quarterly Dividend 2
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
(Date:4/6/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM FOR ... introduces a new revolutionary method and system to ... of miniature antenna modules for multiple purposes including ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... of billions of nerve cells enabling to learn, remember ... smell or fear, millions of neurons in our brain ... by chemical and electrical impulses to compute incoming sensory ... 20,000 - 25,000 genes in our genome, most also ...
... NRGX) today announced the publication in the June 23 issue ... first ever gene therapy trial for Parkinson’s disease and the ... brain cells for any adult neurodegenerative disease. , The ... advanced Parkinson’s disease demonstrated both a lack of adverse events ...
... large mammals at the end of the Ice Age may ... To the list of victims such as woolly mammoths and ... more: a highly carnivorous form of wolf that lived in ... generally thought to have survived the end-Pleistocene extinction relatively unscathed. ...
Cached Biology News:Turn-ons and turn-offs for neurons 2Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 2Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 3Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 4Ice Age extinction claimed highly carnivorous Alaskan wolves 2
... Goat polyclonal to BRF2 Immunogen ... acids 406-419 of Human BRF2. Reactivity / ... in other species. Background Information BRF2 ... RNA polymerase III transcription factor complex required for ...
... 20X Immunogen Proprietary ... concentration for use in KinEASE™ 645nm ... Quality Assurance Routinely evaluated ... assays. Stability ...
Kinase Buffer can be used to assay protein kinase activity...
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
Biology Products: